Mirabegron is a adrenergic agonist (direct acting), used to relaxes the detrusor smooth muscle and increases bladder capacity.
Dose: 25-50 mg
Route: Oral
Plasma half-life: 50 hours
Duration of action: few hours
Bioavailability: 29-35%
Chemical formula: C21H24N4O2S
IUPAC name: 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
Trade name: Myrbetriq, Betmiga, Betanis
Therapeutic uses:
Mirabegron is used to treat overactive bladder.
Note:- Mirabegron has also recently been shown to activate brown fat and increase metabolism.
Side effects: Adverse effects of Mirabegron are as follows:
- Hypertension,
- Dry mouth,
- Nasopharyngitis,
- Urinary tract infection (UTI),
- Headache,
- Influenza,
- Constipation,
- Dizziness,
- Joint pain,
- Cystitis,
- Back pain,
- Upper respiratory tract infection (URTI),
- Sinusitis,
- Diarrhea,
- High heart rate,
- Fatigue,
- Abdominal pain,
- Neoplasms (cancers).
Contraindications:
- It may increase blood pressure and should not be used in patients with uncontrolled hypertension.
- It increases levels of digoxin and also inhibits the CYP2D6 isozyme, which may enhance the effects of other medications metabolized by this pathway (for example, metoprolol).
